lung cancer

[Micromachines] Investigators described a novel in situ cryopreservation technology on the superhydrophobic microwell array chip-chip to preserve the viability of the organoids for future drug sensitivity tests.

[Molecular Therapy-Oncolytics] Researchers clarified whether BRM270 could inhibit the proliferation of CSCs. Endostatin + BRM270 showed anti-tumor effects by reducing tumor volume and increasing survival.

[Cell Death Discovery] When combined with dabrafenib and/or trametinib, Melaleuca alternifolia synergistically reduced the viability of melanoma cells by activating apoptosis.

[Onconova Therapeutics, Inc. (Globe Newswire, Inc.)] Onconova Therapeutics, Inc. announced that the first patient has been dosed in the US Phase I clinical trial of ON 123300, the company’s novel multi-kinase inhibitor, for HR+ HER 2- metastatic breast cancer patients who are refractory to, or progressing on, currently approved CDK 4/6 inhibitors.

[Bristol Myers Squibb, Inc. (Business Wire, Inc.)] Bristol Myers Squibb, Inc. announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy showed a durable survival benefit compared to four cycles of chemotherapy alone after two years of follow-up in previously untreated patients with advanced non-small cell lung cancer (NSCLC).

[Molecular Therapy] Scientists investigated the interconnected pathways underlying the promotion of cisplatin-induced metastases.